Study details
Enrolling now
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
NCT IDNCT04678648ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
134
Study length
about 5.9 years
Ages
18+
Locations
3 sites in CA, CO, TN
About this study
This trial is testing a treatment called RSC-1255 in adults with advanced cancers that haven't responded to other treatments. It has two phases: one to find the right dose and another to see if it works.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take RSC-1255 Dose Escalation
- 2.Take RSC-1255 Dose Expansion
PhasePhase 1
Primary goalMaximum Tolerated Dose (MTD) for RSC-1255 as monotherapy
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapy
Secondary: Adverse event profile of RSC-1255, Overall Survival (OS)
Body systems
Oncology